Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTR-CM and Gene Carrier Follow-up Study
NCT04935021Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2021
- Primary completion
- Jun 2031
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Standard of care-Assistance Publique - Hôpitaux de Paris-COVID-19 in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Major Adverse Cardiovascular Events at 10 years. Started Jun 2021; status: recruiting.
02
Drugs
Standard of care-Assistance Publique - Hôpitaux de Paris-COVID-19
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT04935021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935021.